ADAPTIMMUNE THERAPEUTICS PLC

60 Jubilee Avenue

Abingdon, Oxfordshire OX14 4RX

United Kingdom

 

September 6, 2019

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-7010

Attention: Ada D. Sarmento, Office of Healthcare & Insurance

 

Re:                             Acceleration Request

Adaptimmune Therapeutics plc

Registration Statement on Form S-3

Filed August 30, 2019

File No. 333-233557

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Adaptimmune Therapeutics plc (the “Company”) hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 9:30 a.m. Eastern Standard Time on Tuesday, September 10, 2019, or as soon as possible thereafter.

 

Should you have any questions or comments regarding the foregoing, please call the Company’s counsel, David S. Bakst of Mayer Brown LLP, who can be reached at (212) 506-2551.

 

	Very truly yours,
	Adaptimmune Therapeutics plc
	By:	/s/ Margaret Henry
		Name:	Margaret Henry
		Title:	Corporate Secretary